Tirofiban (hydrochloride)

Tirofiban (L700462) hydrochloride is a selective and reversible platelet integrin receptor (Gp IIb/IIIa) antagonist that inhibits fibrinogen binding to this receptor and has antithrombotic activity. Tirofiban hydrochloride induces proliferation and migration on endothelial cell by inducing production of VEGF. Tirofiban hydrochloride can significantly reduces myocardial no-reflow and ischemia-reperfusion injury by alleviating myocardial microvascular structural and endothelial dysfunction in the ischemic area^[1][2][3]. IC50 & Target: Gp IIb/IIIa receptor^[1]. In Vitro: Tirofiban hydrochloride (0.25, 1, 3 μg/mL; 72 hours) increases proliferation of HAEC cells^[1].
Tirofiban hydrochloride (24 hours) closes the scratch of HUVECs migration within 18 hours^[1].
Tirofiban hydrochloride (0.25, 1 μg/mL; 1 hour) induces production of VEGF after 30 minutes which can stimulates proliferation of endothelial cells^[1]. In Vivo: Tirofiban hydrochloride (60 μg/kg; i.v.; once) shows activity of increasing contraction force, ventricular compliance, and improving heart function by increasing HR, LVESP, dp/dtmax, and reducing LVEDP^[2].
Tirofiban hydrochloride (60 μg/kg; i.v.; once) enhances eNOS activity, decreases iNOS activity and reduces area of no-reflow after reperfusion following AMI^[2].
Tirofiban hydrochloride (50 µg/per; irrigate; once) shows anticoagulant effect with patency rates of 59% at 24 hours after microvascular anastomosis in the crush model^[3].